Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams

Jeremiah D. Momper, Edmund V. Capparelli, Kelly C. Wade, Anand Kantak, Ramasubbareddy Dhanireddy, James J. Cummings, Jonathan H. Nedrelow, Mark L. Hudak, Gratias T. Mundakel, Girija Natarajan, Jamie Gao, Matt Laughon, P. Brian Smith, Daniel K. Benjamin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Fluconazole is an effective agent for prophylaxis of invasive candidiasis in premature infants. The objective of this study was to characterize the population pharmacokinetics (PK) and dosing requirements of fluconazole in infants with birth weights of <750 g. As part of a randomized clinical trial, infants born at <750 g birth weight received intravenous (i.v.) or oral fluconazole at 6 mg/kg of body weight twice weekly. Fluconazole plasma concentrations from samples obtained by either scheduled or scavenged sampling were measured using a liquid chromatography-tandem mass spectrometry assay. Population PK analysis was conducted using NONMEM 7.2. Population PK parameters were allometrically scaled by body weight. Covariates were evaluated by univariable screening followed by multivariable assessment. Fluconazole exposures were simulated in premature infants using the final PK model. A population PK model was developed from 141 infants using 604 plasma samples. Plasma fluconazole PK were best described by a one-compartment model with first-order elimination. Only serum creatinine was an independent predictor for clearance in the final model. The typical population parameter estimate for oral bioavailability in the final model was 99.5%. Scavenged samples did not bias the parameter estimates and were as informative as scheduled samples. Simulations indicated that the study dose maintained fluconazole troughs of >2,000 ng/ml in 80% of simulated infants at week 1 and 59% at week 4 of treatment. Developmental changes in fluconazole clearance are best predicted by serum creatinine in this population. A twice-weekly dose of 6 mg/kg achieves appropriate levels for prevention of invasive candidiasis in extremely premature infants.

Original languageEnglish (US)
Pages (from-to)5539-5545
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Fluconazole
Birth Weight
Premature Infants
Invasive Candidiasis
Pharmacokinetics
Extremely Premature Infants
Population
Creatinine
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. / Momper, Jeremiah D.; Capparelli, Edmund V.; Wade, Kelly C.; Kantak, Anand; Dhanireddy, Ramasubbareddy; Cummings, James J.; Nedrelow, Jonathan H.; Hudak, Mark L.; Mundakel, Gratias T.; Natarajan, Girija; Gao, Jamie; Laughon, Matt; Smith, P. Brian; Benjamin, Daniel K.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 9, 01.09.2016, p. 5539-5545.

Research output: Contribution to journalArticle

Momper, JD, Capparelli, EV, Wade, KC, Kantak, A, Dhanireddy, R, Cummings, JJ, Nedrelow, JH, Hudak, ML, Mundakel, GT, Natarajan, G, Gao, J, Laughon, M, Smith, PB & Benjamin, DK 2016, 'Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams', Antimicrobial Agents and Chemotherapy, vol. 60, no. 9, pp. 5539-5545. https://doi.org/10.1128/AAC.00963-16
Momper, Jeremiah D. ; Capparelli, Edmund V. ; Wade, Kelly C. ; Kantak, Anand ; Dhanireddy, Ramasubbareddy ; Cummings, James J. ; Nedrelow, Jonathan H. ; Hudak, Mark L. ; Mundakel, Gratias T. ; Natarajan, Girija ; Gao, Jamie ; Laughon, Matt ; Smith, P. Brian ; Benjamin, Daniel K. / Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 9. pp. 5539-5545.
@article{be1dc64304d24d3c8d5a744620b3d33e,
title = "Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams",
abstract = "Fluconazole is an effective agent for prophylaxis of invasive candidiasis in premature infants. The objective of this study was to characterize the population pharmacokinetics (PK) and dosing requirements of fluconazole in infants with birth weights of <750 g. As part of a randomized clinical trial, infants born at <750 g birth weight received intravenous (i.v.) or oral fluconazole at 6 mg/kg of body weight twice weekly. Fluconazole plasma concentrations from samples obtained by either scheduled or scavenged sampling were measured using a liquid chromatography-tandem mass spectrometry assay. Population PK analysis was conducted using NONMEM 7.2. Population PK parameters were allometrically scaled by body weight. Covariates were evaluated by univariable screening followed by multivariable assessment. Fluconazole exposures were simulated in premature infants using the final PK model. A population PK model was developed from 141 infants using 604 plasma samples. Plasma fluconazole PK were best described by a one-compartment model with first-order elimination. Only serum creatinine was an independent predictor for clearance in the final model. The typical population parameter estimate for oral bioavailability in the final model was 99.5{\%}. Scavenged samples did not bias the parameter estimates and were as informative as scheduled samples. Simulations indicated that the study dose maintained fluconazole troughs of >2,000 ng/ml in 80{\%} of simulated infants at week 1 and 59{\%} at week 4 of treatment. Developmental changes in fluconazole clearance are best predicted by serum creatinine in this population. A twice-weekly dose of 6 mg/kg achieves appropriate levels for prevention of invasive candidiasis in extremely premature infants.",
author = "Momper, {Jeremiah D.} and Capparelli, {Edmund V.} and Wade, {Kelly C.} and Anand Kantak and Ramasubbareddy Dhanireddy and Cummings, {James J.} and Nedrelow, {Jonathan H.} and Hudak, {Mark L.} and Mundakel, {Gratias T.} and Girija Natarajan and Jamie Gao and Matt Laughon and Smith, {P. Brian} and Benjamin, {Daniel K.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1128/AAC.00963-16",
language = "English (US)",
volume = "60",
pages = "5539--5545",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams

AU - Momper, Jeremiah D.

AU - Capparelli, Edmund V.

AU - Wade, Kelly C.

AU - Kantak, Anand

AU - Dhanireddy, Ramasubbareddy

AU - Cummings, James J.

AU - Nedrelow, Jonathan H.

AU - Hudak, Mark L.

AU - Mundakel, Gratias T.

AU - Natarajan, Girija

AU - Gao, Jamie

AU - Laughon, Matt

AU - Smith, P. Brian

AU - Benjamin, Daniel K.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Fluconazole is an effective agent for prophylaxis of invasive candidiasis in premature infants. The objective of this study was to characterize the population pharmacokinetics (PK) and dosing requirements of fluconazole in infants with birth weights of <750 g. As part of a randomized clinical trial, infants born at <750 g birth weight received intravenous (i.v.) or oral fluconazole at 6 mg/kg of body weight twice weekly. Fluconazole plasma concentrations from samples obtained by either scheduled or scavenged sampling were measured using a liquid chromatography-tandem mass spectrometry assay. Population PK analysis was conducted using NONMEM 7.2. Population PK parameters were allometrically scaled by body weight. Covariates were evaluated by univariable screening followed by multivariable assessment. Fluconazole exposures were simulated in premature infants using the final PK model. A population PK model was developed from 141 infants using 604 plasma samples. Plasma fluconazole PK were best described by a one-compartment model with first-order elimination. Only serum creatinine was an independent predictor for clearance in the final model. The typical population parameter estimate for oral bioavailability in the final model was 99.5%. Scavenged samples did not bias the parameter estimates and were as informative as scheduled samples. Simulations indicated that the study dose maintained fluconazole troughs of >2,000 ng/ml in 80% of simulated infants at week 1 and 59% at week 4 of treatment. Developmental changes in fluconazole clearance are best predicted by serum creatinine in this population. A twice-weekly dose of 6 mg/kg achieves appropriate levels for prevention of invasive candidiasis in extremely premature infants.

AB - Fluconazole is an effective agent for prophylaxis of invasive candidiasis in premature infants. The objective of this study was to characterize the population pharmacokinetics (PK) and dosing requirements of fluconazole in infants with birth weights of <750 g. As part of a randomized clinical trial, infants born at <750 g birth weight received intravenous (i.v.) or oral fluconazole at 6 mg/kg of body weight twice weekly. Fluconazole plasma concentrations from samples obtained by either scheduled or scavenged sampling were measured using a liquid chromatography-tandem mass spectrometry assay. Population PK analysis was conducted using NONMEM 7.2. Population PK parameters were allometrically scaled by body weight. Covariates were evaluated by univariable screening followed by multivariable assessment. Fluconazole exposures were simulated in premature infants using the final PK model. A population PK model was developed from 141 infants using 604 plasma samples. Plasma fluconazole PK were best described by a one-compartment model with first-order elimination. Only serum creatinine was an independent predictor for clearance in the final model. The typical population parameter estimate for oral bioavailability in the final model was 99.5%. Scavenged samples did not bias the parameter estimates and were as informative as scheduled samples. Simulations indicated that the study dose maintained fluconazole troughs of >2,000 ng/ml in 80% of simulated infants at week 1 and 59% at week 4 of treatment. Developmental changes in fluconazole clearance are best predicted by serum creatinine in this population. A twice-weekly dose of 6 mg/kg achieves appropriate levels for prevention of invasive candidiasis in extremely premature infants.

UR - http://www.scopus.com/inward/record.url?scp=84983289212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983289212&partnerID=8YFLogxK

U2 - 10.1128/AAC.00963-16

DO - 10.1128/AAC.00963-16

M3 - Article

VL - 60

SP - 5539

EP - 5545

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

ER -